GLP-1 Medications Are Losing Your Pharmacy Money: Here's What to Do About It

The Blockbuster Drug That Is Bankrupting Pharmacies

GLP-1 receptor agonists are the most talked-about medications in a generation. Ozempic, Wegovy, Mounjaro, and Zepbound have transformed diabetes and obesity treatment, generated billions in revenue for manufacturers, and created unprecedented patient demand. They are also quietly destroying independent pharmacy margins.

According to the National Community Pharmacists Association, 95 percent of pharmacists who dispense GLP-1 drugs report losing money on every fill. Not breaking even — actively losing money. The average loss is more than $42 below the cost to acquire the medication per 30-day supply.

Let that sink in. Every time a patient walks in with a GLP-1 prescription, the pharmacy loses money filling it. And with patient demand at historic highs, those losses are compounding fast.

Why GLP-1s Are Uniquely Devastating for Independent Pharmacies

GLP-1 medications are not ordinary underwater prescriptions. Several factors make them especially damaging to pharmacy economics:

Extreme acquisition costs. A single Ozempic pen package carries a wholesale acquisition cost exceeding $935. Wegovy, which contains the same active ingredient but is approved for weight loss, costs nearly $1,350 per package. These are not $15 generics where a $2 reimbursement shortfall is painful but manageable. When a PBM reimburses below cost on a $935 medication, the pharmacy absorbs a loss that can exceed $40 on a single transaction.

Massive and growing volume. Over 40 million GLP-1 prescriptions were filled in the United States in 2024, and that number continues to climb. As Medicare and Medicaid expand coverage for weight-loss indications, volume will increase further. More prescriptions at a loss means more total losses.

Cash flow pressure. A pharmacy must pay its wholesaler for a $935 medication before receiving reimbursement from the PBM. When that reimbursement arrives weeks later at below-cost rates — sometimes after additional DIR fee clawbacks — the cash flow impact is severe. Independent pharmacies operating on thin margins cannot absorb this kind of float on high-dollar medications.

Patient expectations. Patients want their GLP-1 medications. They have seen the headlines, talked to their doctors, and expect their pharmacy to have these drugs in stock. Turning patients away damages relationships and risks losing them entirely — not just for GLP-1s, but for every other prescription and OTC purchase they make at your pharmacy.

The Impossible Choice Pharmacies Face

The NCPA survey data reveals just how untenable the situation has become. Eighty-six percent of community pharmacies report having to turn patients away because they were losing money on GLP-1 dispensing. Eighty-eight percent have considered no longer filling these prescriptions at all.

And 73 percent of independent pharmacists say they are either contemplating or have already stopped stocking GLP-1 agonists entirely.

This creates a vicious cycle. When independent pharmacies stop stocking GLP-1s, patients are pushed toward chain pharmacies and PBM-owned mail-order operations — the very entities whose reimbursement practices forced independent pharmacies out of the market. The PBM model is working exactly as designed: squeeze independent pharmacies on high-cost medications until they stop dispensing, then capture those patients through vertically integrated channels.

What You Can Actually Do About It

Waiting for PBM reform is not a strategy. Legislative change is coming, but independent pharmacies need to act now. Here are five practical approaches that pharmacies are using to survive the GLP-1 margin crisis.

1. Implement a Cash-Pay GLP-1 Program

The PBM only controls the transaction when insurance is involved. A growing number of pharmacies are offering cash-pay GLP-1 programs that bypass the PBM entirely.

With manufacturer savings programs, authorized generics, and competitive cash pricing, pharmacies can offer patients legitimate GLP-1 access at prices well below retail while maintaining a positive margin. Oral semaglutide, for example, is now available at cash prices starting around $149 per month through certain programs — a fraction of the $935-plus insurance price.

The key is transparent pricing. Patients are increasingly willing to pay cash when they can see the value compared to their insurance copay, deductible, or coverage denial.

2. Build Clinical Services Around GLP-1 Patients

GLP-1 patients are among the most engaged healthcare consumers in your pharmacy. They are actively managing a chronic condition, motivated to improve their health, and willing to invest in their care. That makes them ideal candidates for clinical services that generate revenue independent of PBM reimbursement.

Services to offer GLP-1 patients:

• Medication therapy management — comprehensive medication reviews billed through Medicare Part D or direct-pay
• Weight management counseling — scheduled consultations on nutrition, exercise, and medication adherence
• Metabolic health monitoring — A1C testing, blood pressure checks, and cholesterol screenings at regular intervals
• Injection training and technique assessment — patients new to injectable medications need guidance, and you can provide it as a billable service

Each of these services deepens the patient relationship while generating margin that PBMs cannot claw back.

3. Diversify Revenue to Offset GLP-1 Losses

If GLP-1 dispensing loses $42 per fill, you need to generate $42 in profit elsewhere for every GLP-1 prescription you dispense. The math demands diversification.

Revenue streams that independent pharmacies are using to offset dispensing losses:

• OTC and supplement sales — particularly weight management, metabolic health, and wellness products that GLP-1 patients are already buying somewhere
• Compounding services — custom formulations carry margins that mass-market pharmacies cannot match
• Immunizations and point-of-care testing — high-margin clinical services with growing demand
• Online sales — an e-commerce channel for OTC products, supplements, and health supplies extends your reach beyond walk-in traffic and operates entirely outside PBM economics

The pharmacies that survive the GLP-1 margin squeeze are the ones building multiple revenue streams so that no single category — especially one controlled by PBMs — can threaten the business.

4. Track and Appeal Every Underwater GLP-1 Claim

Document every GLP-1 prescription where reimbursement falls below your acquisition cost. This data serves multiple purposes:

• File reimbursement appeals with each PBM for below-cost claims
• Report to your state board of pharmacy and insurance commissioner
• Provide evidence to state and federal legislators pushing for PBM reform
• Inform your own stocking decisions with hard numbers rather than estimates

Several states now have laws requiring PBMs to reimburse at or above acquisition cost. If your state has passed such legislation, underwater GLP-1 claims may be actionable. Even in states without these protections, a documented pattern of below-cost reimbursement strengthens the case for reform.

5. Control the Patient Relationship Digitally

When a patient leaves your pharmacy because you cannot stock their GLP-1, they do not just take that one prescription with them. They take every other prescription, every OTC purchase, and every clinical service interaction. The total lifetime value of a lost patient far exceeds the loss on any single GLP-1 fill.

Building a digital presence — online refills, OTC ordering, secure messaging, health content — gives patients reasons to stay connected to your pharmacy even when specific medications are complicated. A patient who orders supplements, refills maintenance medications, and schedules flu shots through your online platform is far less likely to switch pharmacies over a single medication category.

The Bigger Picture

GLP-1 medications have exposed a fundamental flaw in the PBM reimbursement model: when pharmacies lose money on the most in-demand medications in the country, the system is broken. Legislative reform is essential, and organizations like the NCPA are making real progress on that front.

But independent pharmacies cannot afford to wait. The ones that will still be operating when reform arrives are the ones that took action today — diversifying revenue, building direct patient relationships, adding clinical services, and creating income streams that no PBM can touch.

If adding an online revenue channel is part of your diversification plan, pharmacy-specific e-commerce platforms can get you there without the cost and complexity of custom development. The goal is straightforward: build enough margin outside the PBM system that underwater prescriptions stop threatening your survival.